BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 15691271)

  • 21. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
    Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
    Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
    Di Marco V; Di Stefano R; Ferraro D; Almasio PL; Bonura C; Giglio M; Parisi P; Cappello M; Alaimo G; Craxì A
    Antivir Ther; 2005; 10(3):431-9. PubMed ID: 15918334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.
    Joh JW; Lee HH; Park JW; Lee DH; Yoo BC; Lee KW; Kim SJ
    Transplant Proc; 2005 Mar; 37(2):1235-7. PubMed ID: 15848680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
    Naoumov NV; Lopes AR; Burra P; Caccamo L; Iemmolo RM; de Man RA; Bassendine M; O'Grady JG; Portmann BC; Anschuetz G; Barrett CA; Williams R; Atkins M
    J Hepatol; 2001 Jun; 34(6):888-94. PubMed ID: 11451173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine.
    Ide T; Kumashiro R; Koga Y; Tanaka E; Hino T; Hisamochi A; Murashima S; Ogata K; Tanaka K; Kuwahara R; Sata M
    Am J Gastroenterol; 2003 Sep; 98(9):2048-51. PubMed ID: 14499786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of hepatitis B virus recurrence after liver transplantation.
    Han YS; Lee SK; Joh JW; Kim SJ; Kwon CH; Park JW; Kim DJ; Park JB
    Transplant Proc; 2006 Sep; 38(7):2123-4. PubMed ID: 16980019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H; Lv Y; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis.
    Shih YH; Yeh SH; Chen PJ; Chou WP; Wang HY; Liu CJ; Lu SF; Chen DS
    Antivir Ther; 2008; 13(4):469-80. PubMed ID: 18672526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention and management of hepatitis B virus reinfection after liver transplantation].
    Ma Y; Tai Q; He XS; Wang GD; Hu AB
    Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(16):1209-12. PubMed ID: 19781163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin.
    Terrault NA; Zhou S; Combs C; Hahn JA; Lake JR; Roberts JP; Ascher NL; Wright TL
    Hepatology; 1996 Dec; 24(6):1327-33. PubMed ID: 8938155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
    Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
    Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection.
    Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V
    Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
    Ferretti G; Merli M; Ginanni Corradini S; Callejon V; Tanzilli P; Masini A; Ferretti S; Iappelli M; Rossi M; Rivanera D; Lilli D; Mancini C; Attili A; Berloco P
    Transplant Proc; 2004 Apr; 36(3):535-8. PubMed ID: 15110584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.